Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Methods Mol Biol. 2023;2576:145-153. doi: 10.1007/978-1-0716-2728-0_11.
Peroxisome proliferator-activated receptors (PPARs) have been exploited as drug targets for combating multiple diseases. Several activators with different selectivity for the PPAR α, γ, and δ subtypes have been introduced into the market or have reached advanced clinical trials. Binding assays are of utmost importance for the discovery and profiling of such PPAR ligands. Binding assays are often based on radioligands, in particular, tritiated molecules are applied. We developed synthetic procedures for tritiating various PPAR agonists and applied these radioligands for setting up a scintillation proximity assay (SPA) for PPAR α, γ, and δ. These SPAs allow to assess the binding affinities of PPAR α, γ, and δ ligands, along with their respective subtype selectivity profiles. Therefore, SPA is an important tool for hit discovery and lead optimization campaigns aimed at identifying next-generation PPAR ligands.
过氧化物酶体增殖物激活受体 (PPARs) 已被用作治疗多种疾病的药物靶点。已经有几种对 PPARα、γ 和δ亚型具有不同选择性的激动剂被引入市场或已进入高级临床试验。结合测定对于发现和分析此类 PPAR 配体至关重要。结合测定通常基于放射性配体,特别是应用氚化分子。我们开发了各种 PPAR 激动剂的氚化合成程序,并将这些放射性配体应用于建立 PPARα、γ 和δ 的闪烁接近测定法 (SPA)。这些 SPA 允许评估 PPARα、γ 和δ配体的结合亲和力,以及它们各自的亚型选择性特征。因此,SPA 是用于发现命中和优化先导化合物的重要工具,旨在识别新一代的 PPAR 配体。